secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kronos Bio, Inc. (—)
CIK:        0001741830
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0001140361-24-026957
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kronos Bio appoints Deborah Knobelman as CFO and COO effective June 3, 2024
---------------------------------------------------------------------------

- Deborah Knobelman appointed CFO and COO, effective June 3, 2024, replacing Sandra Gardiner.
- Knobelman previously served as CFO of Senti Biosciences (SNTI) from 2021 to May 2024.
- Initial base salary $475,000; target annual bonus 40% of salary; signing bonus $50,000.
- Equity grants: 246,390 stock options and 164,260 RSUs with graded vesting schedules.
- She will receive severance benefits under the Company’s Severance Plan for qualifying terminations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1741830/000114036124026957/0001140361-24-026957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1741830/000114036124026957/ef20029602_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-026957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer